Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14326 - 14350 of 15254 in total
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor ... first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and
Huperzine B is a novel acetylcholinesterase inhibitor.
Investigational
Experimental
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.
Experimental
Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.
Investigational
Experimental
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and
AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Investigational
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Investigational
Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.
Experimental
Experimental
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Investigational
Matched Description: … the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and
CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
Investigational
Matched Description: … under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and
TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction).
Investigational
Matched Description: … TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 …
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … 2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of …
Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis).
Investigational
Matched Description: … Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and
Displaying drugs 14326 - 14350 of 15254 in total